Fighting for patient affordability doesn’t necessarily require a scapegoat.
In Search of the ‘Bad Guy’
Related Posts
FDA Approves HIF-2α Inhibitor for Patients With Advanced Renal Cell Carcinoma
The FDA based the approval Merck’s Welireg (belzutifan) on findings from the randomized, open-label, Phase III LITESPARK-005 trial, which compared Welireg to Afinitor for the […]
Kenco, QPharma Collaborate on Improving Supply Chain Challenges
Image Credit: Adobe Stock Images/Kentoh.com Kenco, a provider of third-party logistics (3PL)—which happens to be a major area of coverage for Pharma Commerce—has partnered with […]
FDA Grants Full Approval to Tepmetko for Metastatic NSCLC Subtype
Image credit: iDoPixBox | stock.adobe.com. EMD Serono, Merck KGaA’s biopharmaceutical business, scored a traditional approval for Tepmetko (tepotinib) to treat adults with metastatic non–small cell […]